The U.S. Supreme Court declined to review a ruling that Abbott Laboratories' Humira arthritis drug did not infringe a patent owned by a Johnson & Johnson subsidiary and that threw out a $1.67 billion damage award against Abbott.
Supreme Court won't review J&J-Abbott patent case
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.